Early antiviral treatment response in HBeAg-positive chronic HBV infected-patients with high viral load and normal ALT
The diagnosis and treatment rates of hepatitis B virus (HBV) infection in China in 2020 were 22.1% and 15.0%, respectively, according to the Polaris Observatory HBV Collaborators report. This is still far below the World Health Organization's 2030 hepatitis B elimination target (90% and 80%, respectively, for the diagnosis and treatment rates). Although China has promulgated and implemented a series of policies to eliminate the hepatitis B virus, there are still many HBV infected patients who need to be detected and treated. It has been contoversial whether HBeAg-positive chronic HBV infected-patients with high viral load and normal alanine aminotransferase (ALT), also known as the "immune-tolerant phase," should receive anti-HBV therapy. Hepatologists should pay attention to the patient population known as "immune tolerant," as well as the continuous accumulation of evidence-based medical evidence for early antiviral therapy response. The current focus is on discussing the pros and cons of receiving and recommending anti-HBV therapy at this time for the management of these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology - 31(2023), 3 vom: 20. März, Seite 233-237 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Huang, Y [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alanine Transaminase |
|---|
| Anmerkungen: |
Date Completed 05.05.2023 Date Revised 05.05.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.cn501113-20230313-00108 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356411311 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356411311 | ||
| 003 | DE-627 | ||
| 005 | 20231226070409.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.cn501113-20230313-00108 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1187.xml |
| 035 | |a (DE-627)NLM356411311 | ||
| 035 | |a (NLM)37137846 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Huang, Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early antiviral treatment response in HBeAg-positive chronic HBV infected-patients with high viral load and normal ALT |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.05.2023 | ||
| 500 | |a Date Revised 05.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The diagnosis and treatment rates of hepatitis B virus (HBV) infection in China in 2020 were 22.1% and 15.0%, respectively, according to the Polaris Observatory HBV Collaborators report. This is still far below the World Health Organization's 2030 hepatitis B elimination target (90% and 80%, respectively, for the diagnosis and treatment rates). Although China has promulgated and implemented a series of policies to eliminate the hepatitis B virus, there are still many HBV infected patients who need to be detected and treated. It has been contoversial whether HBeAg-positive chronic HBV infected-patients with high viral load and normal alanine aminotransferase (ALT), also known as the "immune-tolerant phase," should receive anti-HBV therapy. Hepatologists should pay attention to the patient population known as "immune tolerant," as well as the continuous accumulation of evidence-based medical evidence for early antiviral therapy response. The current focus is on discussing the pros and cons of receiving and recommending anti-HBV therapy at this time for the management of these patients | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antiviral therapy | |
| 650 | 4 | |a Chronic hepatitis B | |
| 650 | 4 | |a Immune-tolerant phase | |
| 650 | 7 | |a Hepatitis B e Antigens |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Alanine Transaminase |2 NLM | |
| 650 | 7 | |a EC 2.6.1.2 |2 NLM | |
| 650 | 7 | |a DNA, Viral |2 NLM | |
| 700 | 1 | |a Du, B Y |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Q |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology |d 1998 |g 31(2023), 3 vom: 20. März, Seite 233-237 |w (DE-627)NLM096493321 |x 1007-3418 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:3 |g day:20 |g month:03 |g pages:233-237 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.cn501113-20230313-00108 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 3 |b 20 |c 03 |h 233-237 | ||